Robert E Landry is EVP Finance CFO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 23,693 shares of REGN, which is worth approximately $27.2 Million. The most recent transaction as insider was on Dec 11, 2023, when has been sold 3,221 shares (Common Stock) at a price of $844.09 per share, resulting in proceeds of $2,718,813. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23.7K
0% 3M change
25.26% 12M change
Total Value Held $27.2 Million

Robert E Landry Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 11 2023
SELL
Payment of exercise price or tax liability
$2,718,813 $844.09 p/Share
3,221 Reduced 10.5%
27,465 Common Stock
Dec 08 2023
SELL
Payment of exercise price or tax liability
$854,759 $843.79 p/Share
1,013 Reduced 3.2%
30,686 Common Stock
Aug 23 2023
SELL
Open market or private sale
$188,212 $844.0 p/Share
223 Reduced 0.7%
31,699 Common Stock
Mar 28 2023
SELL
Open market or private sale
$828,710 $822.95 p/Share
1,007 Reduced 3.06%
31,922 Common Stock
Mar 27 2023
SELL
Payment of exercise price or tax liability
$2,304,699 $825.17 p/Share
2,793 Reduced 7.78%
33,112 Common Stock
Mar 27 2023
SELL
Open market or private sale
$150,813 $824.12 p/Share
183 Reduced 0.55%
32,929 Common Stock
Mar 27 2023
BUY
Exercise of conversion of derivative security
$1,445,710 $380.45 p/Share
3,800 Added 9.71%
35,316 Common Stock
Feb 06 2023
SELL
Open market or private sale
$594,260 $790.24 p/Share
752 Reduced 2.29%
32,105 Common Stock
Feb 03 2023
SELL
Open market or private sale
$564,965 $764.5 p/Share
739 Reduced 2.25%
32,105 Common Stock
Feb 03 2023
SELL
Payment of exercise price or tax liability
$1,740,603 $774.29 p/Share
2,248 Reduced 6.4%
32,857 Common Stock
Feb 03 2023
BUY
Exercise of conversion of derivative security
$1,145,760 $381.92 p/Share
3,000 Added 7.87%
35,105 Common Stock
Dec 16 2022
BUY
Grant, award, or other acquisition
-
3,853 Added 10.5%
32,844 Common Stock
Dec 09 2022
SELL
Payment of exercise price or tax liability
$370,613 $753.28 p/Share
492 Reduced 1.67%
28,991 Common Stock
Dec 08 2022
SELL
Payment of exercise price or tax liability
$1,737,668 $768.54 p/Share
2,261 Reduced 7.12%
29,483 Common Stock
Dec 08 2022
BUY
Exercise of conversion of derivative security
$1,145,760 $381.92 p/Share
3,000 Added 8.63%
31,744 Common Stock
Dec 02 2022
SELL
Open market or private sale
$462,904 $758.86 p/Share
610 Reduced 2.08%
28,744 Common Stock
Dec 01 2022
SELL
Payment of exercise price or tax liability
$1,437,061 $760.35 p/Share
1,890 Reduced 6.05%
29,354 Common Stock
Dec 01 2022
BUY
Exercise of conversion of derivative security
$954,800 $381.92 p/Share
2,500 Added 7.41%
31,244 Common Stock
Nov 01 2022
SELL
Open market or private sale
$365,307 $757.9 p/Share
482 Reduced 1.65%
28,744 Common Stock
Oct 31 2022
SELL
Payment of exercise price or tax liability
$1,140,382 $751.24 p/Share
1,518 Reduced 4.94%
29,226 Common Stock
Oct 31 2022
BUY
Exercise of conversion of derivative security
$763,840 $381.92 p/Share
2,000 Added 6.11%
30,744 Common Stock
Oct 17 2022
SELL
Open market or private sale
$264,741 $739.5 p/Share
358 Reduced 1.23%
28,744 Common Stock
Oct 14 2022
SELL
Payment of exercise price or tax liability
$849,397 $743.78 p/Share
1,142 Reduced 3.78%
29,102 Common Stock
Oct 14 2022
BUY
Exercise of conversion of derivative security
$572,880 $381.92 p/Share
1,500 Added 4.73%
30,244 Common Stock
Apr 11 2022
SELL
Open market or private sale
$1,367,639 $734.5 p/Share
1,862 Reduced 6.08%
28,744 Common Stock
REL

Robert E Landry

EVP Finance CFO
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN